M2e-based universal influenza a vaccines

Vaccines

Volumn 3, Issue 1, 2015, Pages 105-136

  Deng, Lei ^a,b   Cho, Ki Joon ^a,b   Fiers, Walter ^a,b   Saelens, Xavier ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Influenza; Matrix protein 2; Vaccines

Indexed keywords

AMANTADINE; EPITOPE; INFLUENZA VACCINE; M2E VACCINE; MATRIX PROTEIN 2; RIMANTADINE; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); COMPLEMENT DEPENDENT CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA A; INFLUENZA VIRUS A; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR DYNAMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN EXPRESSION; REVIEW; SEQUENCE ALIGNMENT; TANDEM REPEAT; VIRUS GENOME;

EID: 85016872770     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3010105     Document Type: Review

References (149)

1. CDC. Estimates of deaths associated with seasonal influenza—United States, 1976–2007. MMWR Morb. Mortal. Wkly. Rep. 2010, 59,1057–1062.
2. Barker, W.H.; Mullooly, J.P. Pneumonia and influenza deaths during epidemics: Implications for prevention. Arch. Intern. Med. 1982, 142, 85–89.
3. Nair, H.; Brooks, W.A.; Katz, M.; Roca, A.; Berkley, J.A.; Madhi, S.A.; Simmerman, J.M.; Gordon, A.; Sato, M.; Howie, S.; et al. Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta-analysis. Lancet 2011, 378, 1917–1930.
4. Patterson, K.D.; Pyle, G.F. The geography and mortality of the 1918 influenza pandemic. Bull. Hist. Med. 1991, 65, 4–21.
5. Johnson, N.P.; Mueller, J. Updating the accounts: Global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull. Hist. Med. 2002, 76, 105–115.
6. Simonsen, L.; Clarke, M.J.; Williamson, G.D.; Stroup, D.F.; Arden, N.H.; Schonberger, L.B. The impact of influenza epidemics on mortality: Introducing a severity index. Am. J. Public Health 1997, 87, 1944–1950.
7. Dawood, F.S.; Iuliano, A.D.; Reed, C.; Meltzer, M.I.; Shay, D.K.; Cheng, P.Y.; Bandaranayake, D.; Breiman, R.F.; Brooks, W.A.; Buchy, P.; et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study. Lancet Infect. Dis. 2012, 12, 687–695.
8. Qi, X.; Jiang, D.; Wang, H.; Zhuang, D.; Ma, J.; Fu, J.; Qu, J.; Sun, Y.; Yu, S.; Meng, Y.; et al.Calculating the burden of disease of avian-origin H7N9 infections in China. Br. Med. J. Open 2014, 4, e004189.
9. Webster, R.G.; Bean, W.J.; Gorman, O.T.; Chambers, T.M.; Kawaoka, Y. Evolution and ecology of influenza A viruses. Microbiol. Rev.1992, 56, 152–179.
10. Tong, S.; Zhu, X.; Li, Y.; Shi, M.; Zhang, J.; Bourgeois, M.; Yang, H.; Chen, X.; Recuenco, S.; Gomez, J.; et al. New world bats harbor diverse influenza A viruses. PLOS Pathog. 2013, 9, e1003657.
11. Chaipan, C.; Kobasa, D.; Bertram, S.; Glowacka, I.; Steffen, I.; Tsegaye, T.S.; Takeda, M.; Bugge, T.H.; Kim, S.; Park, Y.; et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 2009, 83, 3200–3211.
12. Matrosovich, M.N.; Matrosovich, T.Y.; Gray, T.; Roberts, N.A.; Klenk, H.D. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl. Acad. Sci. USA 2004, 101, 4620–4624.
13. Srivastava, B.; Blazejewska, P.; Hessmann, M.; Bruder, D.; Geffers, R.; Mauel, S.; Gruber, A.D.; Schughart, K. Host genetic background strongly influences the response to influenza a virus infections. PLOS ONE 2009, 4, e4857.
14. Gouarin, S.; Vabret, A.; Dina, J.; Petitjean, J.; Brouard, J.; Cuvillon-Nimal, D.; Freymuth, F. Study of influenza C virus infection in France. J. Med. Virol.2008, 80, 1441–1446.
15. Kauppila, J.; Ronkko, E.; Juvonen, R.; Saukkoriipi, A.; Saikku, P.; Bloigu, A.; Vainio, O.; Ziegler, T. Influenza C virus infection in military recruits—Symptoms and clinical manifestation. J. Med. Virol. 2014, 86, 879–885.
16. Matsuzaki, Y.; Katsushima, N.; Nagai, Y.; Shoji, M.; Itagaki, T.; Sakamoto, M.; Kitaoka, S.; Mizuta, K.; Nishimura, H. Clinical features of influenza C virus infection in children. J. Infect. Dis. 2006, 193, 1229–1235.
17. Kendal, A.P. Cold-adapted live attenuated influenza vaccines developed in Russia: Can they contribute to meeting the needs for influenza control in other countries? Eur. J. Epidemiol. 1997, 13, 591–609.
18. Isakova-Sivak, I.; Chen, L.M.; Matsuoka, Y.; Voeten, J.T.; Kiseleva, I.; Heldens, J.G.; den Bosch, H.; Klimov, A.; Rudenko, L.; Cox, N.J.; et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology 2011, 412, 297–305.
19. Durviaux, S.; Treanor, J.; Beran, J.; Duval, X.; Esen, M.; Feldman, G.; Frey, S.E.; Launay, O.; Leroux-Roels, G.; McElhaney, J.E.; et al. Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008–2009 vaccine efficacy trial. Clin. Vaccine Immunol. 2014, 21, 271–279.
20. El Moussi, A.; Pozo, F.; Ben Hadj Kacem, M.A.; Ledesma, J.; Cuevas, M.T.; Casas, I.; Slim, A.; Virological Surveillance of Influenza Viruses during the 2008–09, 2009–10 and 2010–11 Seasons in Tunisia. PLOS ONE 2013, 8, e74064.
21. Heikkinen, T.; Ikonen, N.; Ziegler, T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999–2012. Clin. Infect. Dis. 2014, doi:10.1093/cid/ciu664.
22. McKeage, K. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix(R) quadrivalent): A review of its use in the prevention of disease caused by influenza A and B. Drugs 2013, 73, 1587–1594.
23. Greenberg, D.P.; Robertson, C.A.; Landolfi, V.A.; Bhaumik, A.; Senders, S.D.; Decker, M.D. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr. Infect. Dis. J. 2014, 33, 630–636.
24. Xu, R.; Ekiert, D.C.; Krause, J.C.; Hai, R.; Crowe, J.E., Jr.; Wilson, I.A. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010, 328, 357–360.
25. Kirchenbaum, G.A.; Ross, T.M. Eliciting broadly protective antibody responses against influenza. Curr. Opin. Immunol. 2014, 28, 71–76.
26. Vasin, A.V.; Temkina, O.A.; Egorov, V.V.; Klotchenko, S.A.; Plotnikova, M.A.; Kiselev, O.I. Molecular mechanisms enhancing the proteome of influenza A viruses: An overview of recently discovered proteins. Virus Res. 2014, 185, 53–63.
27. Lamb, R.A.; Choppin, P.W. Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 1981, 112, 729–737.
28. Lamb, R.A.; Lai, C.J.; Choppin, P.W. Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: Colinear and interrupted mRNAs code for overlapping proteins. Proc. Natl. Acad. Sci. USA 1981, 78, 4170–4174.
29. Leiding, T.; Wang, J.; Martinsson, J.; DeGrado, W.F.; Arskold, S.P. Proton and cation transport activity of the M2 proton channel from influenza A virus. Proc. Natl. Acad. Sci. USA 2010, 107, 15409–15414.
30. Stauffer, S.; Feng, Y.; Nebioglu, F.; Heilig, R.; Picotti, P.; Helenius, A. Stepwise priming by acidic pH and a high K+ concentration is required for efficient uncoating of influenza A virus cores after penetration. J. Virol. 2014, 88, 13029–13046.
31. Helenius, A. Unpacking the incoming influenza virus. Cell 1992, 69, 577–578.
32. Neirynck, S.; Deroo, T.; Saelens, X.; Vanlandschoot, P.; Jou, W.M.; Fiers, W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999, 5, 1157–1163.
33. Zhou, C.; Zhou, L.; Chen, Y.H. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Vaccine 2012, 30, 3463–3469.
34. Black, R.A.; Rota, P.A.; Gorodkova, N.; Klenk, H.D.; Kendal, A.P. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. 1993, 74, 143–146.
35. Wise, H.M.; Hutchinson, E.C.; Jagger, B.W.; Stuart, A.D.; Kang, Z.H.; Robb, N.; Schwartzman, L.M.; Kash, J.C.; Fodor, E.; Firth, A.E.; et al.Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain. PLOS Pathog. 2012, 8, e1002998.
36. Stouffer, A.L.; Acharya, R.; Salom, D.; Levine, A.S.; di Costanzo, L.; Soto, C.S.; Tereshko, V.; Nanda, V.; Stayrook, S.; DeGrado, W.F. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008, 451, 596–599.
37. Khurana, E.; dal Peraro, M.; DeVane, R.; Vemparala, S.; DeGrado, W.F.; Klein, M.L. Molecular dynamics calculations suggest a conduction mechanism for the M2 proton channel from influenza A virus. Proc. Natl. Acad. Sci. USA 2009, 106, 1069–1074.
38. Sharma, M.; Yi, M.; Dong, H.; Qin, H.; Peterson, E.; Busath, D.D.; Zhou, H.X.; Cross, T.A. Insight into the mechanism of the influenza A proton channel from a structure in a lipid bilayer. Science 2010, 330, 509–512.
39. Pielak, R.M.; Schnell, J.R.; Chou, J.J. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc. Natl. Acad. Sci. USA 2009, 106, 7379–7384.
40. Schnell, J.R.; Chou, J.J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008, 451, 591–595.
41. Pielak, R.M.; Oxenoid, K.; Chou, J.J. Structural investigation of rimantadine inhibition of the AM2-BM2 chimera channel of influenza viruses. Structure 2011, 19, 1655–1663.
42. McCown, M.F.; Pekosz, A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J. Virol. 2005, 79, 3595–3605.
43. McCown, M.F.; Pekosz, A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J. Virol. 2006, 80, 8178–8189.
44. Rossman, J.S.; Jing, X.; Leser, G.P.; Balannik, V.; Pinto, L.H.; Lamb, R.A. Influenza virus m2 ion channel protein is necessary for filamentous virion formation. J. Virol. 2010, 84, 5078–5088.
45. Rossman, J.S.; Jing, X.; Leser, G.P.; Lamb, R.A. Influenza virus M2 protein mediates ESCRT-independent membrane scission. Cell 2010, 142, 902–913.
46. Ciampor, F.; Bayley, P.M.; Nermut, M.V.; Hirst, E.M.; Sugrue, R.J.; Hay, A.J. Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Golgi compartment. Virology 1992, 188, 14–24.
47. Betakova, T.; Ciampor, F.; Hay, A.J. Influence of residue 44 on the activity of the M2 proton channel of influenza A virus. J. Gen. Virol. 2005, 86, 181–184.
48. Grambas, S.; Hay, A.J. Maturation of influenza A virus hemagglutinin—Estimates of the pH encountered during transport and its regulation by the M2 protein. Virology 1992, 190, 11–18.
49. Ichinohe, T.; Pang, I.K.; Iwasaki, A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat. Immunol. 2010, 11, 404–410.
50. Deretic, V.; Levine, B. Autophagy, immunity, and microbial adaptations. Cell Host Microbe 2009, 5, 527–549.
51. Gannage, M.; Dormann, D.; Albrecht, R.; Dengjel, J.; Torossi, T.; Ramer, P.C.; Lee, M.; Strowig, T.; Arrey, F.; Conenello, G.; et al. Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe 2009, 6, 367–380.
52. Beale, R.; Wise, H.; Stuart, A.; Ravenhill, B.J.; Digard, P.; Randow, F. A LC3-interacting motif in the influenza A virus M2 protein is required to subvert autophagy and maintain virion stability. Cell Host Microbe 2014, 15, 239–247.
53. Feng, J.; Zhang, M.; Mozdzanowska, K.; Zharikova, D.; Hoff, H.; Wunner, W.; Couch, R.B.; Gerhard, W. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol. J. 2006, doi:10.1186/1743-422X-3-102.
54. Hutchinson, E.C.; Charles, P.D.; Hester, S.S.; Thomas, B.; Trudgian, D.; Martinez-Alonso, M.; Fodor, E. Conserved and host-specific features of influenza virion architecture. Nat. Commun.2014, doi:10.1038/ncomms5816.
55. Heinen, P.P.; de Boer-Luijtze, E.A.; Bianchi, A.T. Respiratory and systemic humoral and cellular immune responses of pigs to a heterosubtypic influenza A virus infection. J. Gen. Virol.2001, 82, 2697–2707.
56. Wolf, A.I.; Mozdzanowska, K.; Williams, K.L.; Singer, D.; Richter, M.; Hoffmann, R.; Caton, A.J.; Otvos, L.; Erikson, J. Vaccination with M2e-based multiple antigenic peptides: Characterization of the B cell response and protection efficacy in inbred and outbred mice. PLOS ONE 2011, 6, e28445.
57. Hemmatzadeh, F.; Sumarningsih, S.; Tarigan, S.; Indriani, R.; Dharmayanti, N.L.; Ebrahimie, E.; Igniatovic, J. Recombinant M2e protein-based ELISA: A novel and inexpensive approach for differentiating avian influenza infected chickens from vaccinated ones. PLOS ONE 2013, 8, e56801.
58. Lambrecht, B.; Steensels, M.; van Borm, S.; Meulemans, G.; van den Berg, T. Development of an M2e-specific enzyme-linked immunosorbent assay for differentiating infected from vaccinated animals. Avian Dis. 2007, 51, 221–226.
59. Zhong, W.; Reed, C.; Blair, P.J.; Katz, J.M.; Hancock, K. Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans. J. Infect. Dis. 2014, 209, 986–994.
60. Jameson, J.; Cruz, J.; Terajima, M.; Ennis, F.A. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J. Immunol. 1999, 162, 7578–7583.
61. Jameson, J.; Cruz, J.; Ennis, F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 1998, 72, 8682–8689.
62. Gianfrani, C.; Oseroff, C.; Sidney, J.; Chesnut, R.W.; Sette, A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum. Immunol. 2000, 61, 438–452.
63. Canaday, D.H.; Gehring, A.; Leonard, E.G.; Eilertson, B.; Schreiber, J.R.; Harding, C.V.; Boom, W.H. T-cell hybridomas from HLA-transgenic mice as tools for analysis of human antigen processing. J. Immunol. Methods 2003, 281, 129–142.
64. Eliasson, D.G.; el Bakkouri, K.; Schon, K.; Ramne, A.; Festjens, E.; Lowenadler, B.; Fiers, W.; Saelens, X. CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26, 1243–1252.
65. Pejoski, D.; Zeng, W.; Rockman, S.; Brown, L.E.; Jackson, D.C. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol. Cell Biol. 2010, 88, 605–611.
66. De Filette, M.; Ysenbaert, T.; Roose, K.; Schotsaert, M.; Roels, S.; Goossens, E.; Schepens, B.; Fiers, W.; Saelens, X. Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective. J. Gen. Virol. 2011, 92, 301–306.
67. Misplon, J.A.; Lo, C.Y.; Gabbard, J.D.; Tompkins, S.M.; Epstein, S.L. Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 2010, 28, 5817–5827.
68. Lee, Y.N.; Kim, M.C.; Lee, Y.T.; Hwang, H.S.; Cho, M.K.; Lee, J.S.; Ko, E.J.; Kwon, Y.M.; Kang, S.M. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection. Vaccine 2014, 32, 4578–4585.
69. Kim, M.C.; Song, J.M.; Eunju, O.; Kwon, Y.M.; Lee, Y.J.; Compans, R.W.; Kang, S.M. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol. Ther. 2013, 21, 485–492.
70. Leclerc, D.; Rivest, M.; Babin, C.; Lopez-Macias, C.; Savard, P. A novel M2e based flu vaccine formulation for dogs. PLOS ONE 2013, 8, e77084.
71. Petukhova, N.V.; Gasanova, T.V.; Stepanova, L.A.; Rusova, O.A.; Potapchuk, M.V.; Korotkov, A.V.; Skurat, E.V.; Tsybalova, L.M.; Kiselev, O.I.; Ivanov, P.A.; et al. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors. Curr. Pharm. Des.2013, 19, 5587–5600.
72. Tyulkina, L.G.; Skurat, E.V.; Frolova, O.Y.; Komarova, T.V.; Karger, E.M.; Atabekov, I.G. New viral vector for superproduction of epitopes of vaccine proteins in plants. Acta Naturae 2011, 3, 73–82.
73. Denis, J.; Acosta-Ramirez, E.; Zhao, Y.; Hamelin, M.E.; Koukavica, I.; Baz, M.; Abed, Y.; Savard, C.; Pare, C.; Lopez Macias, C.; et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26, 3395–3403.
74. Matic, S.; Rinaldi, R.; Masenga, V.; Noris, E. Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol.2011, doi:10.1186/1472-6750-11-106.
75. Ameiss, K.; Ashraf, S.; Kong, W.; Pekosz, A.; Wu, W.H.; Milich, D.; Billaud, J.N.; Curtiss, R., 3rd. Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype. Vaccine 2010, 28, 6704–6713.
76. Hashemi, H.; Pouyanfard, S.; Bandehpour, M.; Noroozbabaei, Z.; Kazemi, B.; Saelens, X.; Mokhtari-Azad, T. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLOS ONE 2012, 7, e45765.
77. Bessa, J.; Schmitz, N.; Hinton, H.J.; Schwarz, K.; Jegerlehner, A.; Bachmann, M.F. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: Implications for vaccine design. Eur. J. Immunol.2008, 38, 114–126.
78. De Filette, M.; Martens, W.; Roose, K.; Deroo, T.; Vervalle, F.; Bentahir, M.; Vandekerckhove, J.; Fiers, W.; Saelens, X. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J. Biol. Chem. 2008, 283, 11382–11387.
79. Andersson, A.M.; Hakansson, K.O.; Jensen, B.A.; Christensen, D.; Andersen, P.; Thomsen, A.R.; Christensen, J.P. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLOS ONE 2012, 7, e46395.
80. Mozdzanowska, K.; Feng, J.; Eid, M.; Kragol, G.; Cudic, M.; Otvos, L., Jr.; Gerhard, W. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21, 2616–2626.
81. Mozdzanowska, K.; Zharikova, D.; Cudic, M.; Otvos, L.; Gerhard, W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol. J. 2007, doi:10.1186/1743-422X-4-118.
82. Zhao, G.; Lin, Y.; Du, L.; Guan, J.; Sun, S.; Sui, H.; Kou, Z.; Chan, C.C.; Guo, Y.; Jiang, S. ; et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol. J. 2010, doi:10.1186/1743-422X-7-9.
83. Zhao, G.; Sun, S.; Du, L.; Xiao, W.; Ru, Z.; Kou, Z.; Guo, Y.; Yu, H.; Jiang, S.; Lone, Y.; et al. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol. J. 2010, doi:10.1186/1743-422X-7-15.
84. Liu, W.; Li, H.; Chen, Y.H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol. Med. Microbiol. 2003, 35, 141–146.
85. Fan, J.; Liang, X.; Horton, M.S.; Perry, H.C.; Citron, M.P.; Heidecker, G.J.; Fu, T.M.; Joyce, J.; Przysiecki, C.T.; Keller, P.M.; et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22, 2993–3003.
86. Fu, T.M.; Grimm, K.M.; Citron, M.P.; Freed, D.C.; Fan, J.; Keller, P.M.; Shiver, J.W.; Liang, X.; Joyce, J.G. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27, 1440–1447.
87. Turley, C.B.; Rupp, R.E.; Johnson, C.; Taylor, D.N.; Wolfson, J.; Tussey, L.; Kavita, U.; Stanberry, L.; Shaw, A. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011, 29, 5145–5152.
88. Huleatt, J.W.; Nakaar, V.; Desai, P.; Huang, Y.; Hewitt, D.; Jacobs, A.; Tang, J.; McDonald, W.; Song, L.; Evans, R.K.; et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26, 201–214.
89. Talbot, H.K.; Rock, M.T.; Johnson, C.; Tussey, L.; Kavita, U.; Shanker, A.; Shaw, A.R.; Taylor, D.N. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLOS ONE 2010, 5, e14442.
90. Alvarez, P.; Zylberman, V.; Ghersi, G.; Boado, L.; Palacios, C.; Goldbaum, F.; Mattion, N. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice. Vaccine 2013, 31, 806–812.
91. Herve, P.L.; Raliou, M.; Bourdieu, C.; Dubuquoy, C.; Petit-Camurdan, A.; Bertho, N.; Eleouet, J.F.; Chevalier, C.; Riffault, S. A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2. J. Virol. 2014, 88, 325–338.
92. Redding, L.; Weiner, D.B. DNA vaccines in veterinary use. Expert Rev. Vaccines 2009, 8, 1251–1276.
93. Wei, H.; Lenz, S.D.; Thompson, D.H.; Pogranichniy, R.M. DNA-vaccine platform development against H1N1 subtype of swine influenza A viruses. Viral Immunol.2012, 25, 297–305.
94. Wang, B.; Yu, H.; Yang, F.R.; Huang, M.; Ma, J.H.; Tong, G.Z. Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin. Virol. J. 2012, doi:10.1186/1743-422X-9-12.
95. Park, K.S.; Seo, Y.B.; Lee, J.Y.; Im, S.J.; Seo, S.H.; Song, M.S.; Choi, Y.K.; Sung, Y.C. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Vaccine 2011, 29, 5481–5487.
96. Lalor, P.A.; Webby, R.J.; Morrow, J.; Rusalov, D.; Kaslow, D.C.; Rolland, A.; Smith, L.R. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J. Infect. Dis. 2008, 197, 1643–1652.
97. Okuda, K.; Ihata, A.; Watabe, S.; Okada, E.; Yamakawa, T.; Hamajima, K.; Yang, J.; Ishii, N.; Nakazawa, M.; Ohnari, K.; et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 2001, 19, 3681–3691.
98. Madan, V.; Castello, A.; Carrasco, L. Viroporins from RNA viruses induce caspase-dependent apoptosis. Cell Microbiol. 2008, 10, 437–451.
99. Zhou, D.; Wu, T.L.; Emmer, K.L.; Kurupati, R.; Tuyishime, S.; Li, Y.; Giles-Davis, W.; Zhou, X.; Xiang, Z.; Liu, Q.; et al. Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus. Mol. Ther. 2013, 21, 696–706.
100. Kim, E.H.; Park, H.J.; Han, G.Y.; Song, M.K.; Pereboev, A.; Hong, J.S.; Chang, J.; Byun, Y.H.; Seong, B.L.; Nguyen, H.H. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice. J. Virol. 2014, 88, 9693–9703.
101. Layton, S.L.; Kapczynski, D.R.; Higgins, S.; Higgins, J.; Wolfenden, A.D.; Liljebjelke, K.A.; Bottje, W.G.; Swayne, D.; Berghman, L.R.; Kwon, Y.M.; et al. Vaccination of chickens with recombinant Salmonella expressing M2e and CD154 epitopes increases protection and decreases viral shedding after low pathogenic avian influenza challenge. Poult. Sci. 2009, 88, 2244–2252.
102. Hessel, A.; Savidis-Dacho, H.; Coulibaly, S.; Portsmouth, D.; Kreil, T.R.; Crowe, B.A.; Schwendinger, M.G.; Pilz, A.; Barrett, P.N.; Falkner, F.G; et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLOS ONE 2014, 9, e88340
103. Okuno, Y.; Isegawa, Y.; Sasao, F.; Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 1993, 67, 2552–2558.
104. DiLillo, D.J.; Tan, G.S.; Palese, P.; Ravetch, J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 2014, 20, 143–151.
105. Berendt, R.F. Simian model for the evaluation of immunity to influenza. Infect. Immun. 1974, 9, 101–105.
106. Bodewes, R.; Rimmelzwaan, G.F.; Osterhaus, A.D. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev. Vaccines 2010, 9, 59–72.
107. Van Riel, D.; Munster, V.J.; de Wit, E.; Rimmelzwaan, G.F.; Fouchier, R.A.; Osterhaus, A.D.; Kuiken, T. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am. J. Pathol. 2007, 171, 1215–1223.
108. Maher, J.A.; DeStefano, J. The ferret: An animal model to study influenza virus. Lab. Anim. (NY) 2004, 33, 50–53.
109. Ito, T.; Couceiro, J.N.; Kelm, S.; Baum, L.G.; Krauss, S.; Castrucci, M.R.; Donatelli, I.; Kida, H.; Paulson, J.C.; Webster, R.G; et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J. Virol. 1998, 72, 7367–7373.
110. Ma, W.; Kahn, R.E.; Richt, J.A. The pig as a mixing vessel for influenza viruses: Human and veterinary implications. J. Mol. Genet. Med. 2008, 3, 158–166.
111. Heinen, P.P.; Rijsewijk, F.A.; de Boer-Luijtze, E.A.; Bianchi, A.T. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J. Gen. Virol. 2002, 83, 1851–1859.
112. Reese, K.A.; Lupfer, C.; Johnson, R.C.; Mitev, G.M.; Mullen, V.M.; Geller, B.L.; Pastey, M. A novel lactococcal vaccine expressing a peptide from the M2 antigen of H5N2 highly pathogenic avian Influenza A virus prolongs survival of vaccinated chickens. Vet. Med. Int. 2013, doi:10.1155/2013/316926.
113. Zhang, X.; Liu, M.; Liu, C.; Du, J.; Shi, W.; Sun, E.; Li, H.; Li, J.; Zhang, Y. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens. Intervirology 2011, 54, 290–299.
114. Zebedee, S.L.; Lamb, R.A. Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 1988, 62, 2762–2772.
115. Treanor, J.J.; Tierney, E.L.; Zebedee, S.L.; Lamb, R.A.; Murphy, B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 1990, 64, 1375–1377.
116. Zharikova, D.; Mozdzanowska, K.; Feng, J.; Zhang, M.; Gerhard, W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J. Virol. 2005, 79, 6644–6654.
117. Liu, W.; Zou, P.; Chen, Y.H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol. Lett.2004, 93, 131–136.
118. Grandea, A.G., 3rd; Olsen, O.A.; Cox, T.C.; Renshaw, M.; Hammond, P.W.; Chan-Hui, P.Y.; Mitcham, J.L.; Cieplak, W.; Stewart, S.M.; Grantham, M.L; et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc. Natl. Acad. Sci. USA 2010, 107, 12658–12663.
119. Fu, T.M.; Freed, D.C.; Horton, M.S.; Fan, J.; Citron, M.P.; Joyce, J.G.; Garsky, V.M.; Casimiro, D.R.; Zhao, Q.; Shiver, J.W.; et al. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 2009, 385, 218–226.
120. Ernst, W.A.; Kim, H.J.; Tumpey, T.M.; Jansen, A.D.; Tai, W.; Cramer, D.V.; Adler-Moore, J.P.; Fujii, G. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006, 24, 5158–5168.
121. Tompkins, S.M.; Zhao, Z.S.; Lo, C.Y.; Misplon, J.A.; Liu, T.; Ye, Z.; Hogan, R.J.; Wu, Z.; Benton, K.A.; Tumpey, T.M; et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 2007, 13, 426–435.
122. Jegerlehner, A.; Schmitz, N.; Storni, T.; Bachmann, M.F. Influenza A vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004, 172, 5598–5605.
123. El Bakkouri, K.; Descamps, F.; de Filette, M.; Smet, A.; Festjens, E.; Birkett, A.; van Rooijen, N.; Verbeek, S.; Fiers, W.; Saelens, X. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 2011, 186, 1022–1031
124. Wang, R.; Song, A.; Levin, J.; Dennis, D.; Zhang, N.J.; Yoshida, H.; Koriazova, L.; Madura, L.; Shapiro, L.; Matsumoto, A; et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res.2008, 80, 168–177.
125. Wu, F.; Huang, J.H.; Yuan, X.Y.; Huang, W.S.; Chen, Y.H. Characterization of immunity induced by M2e of influenza virus. Vaccine 2007, 25, 8868–8873.
126. Markine-Goriaynoff, D.; Coutelier, J.P. Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J. Virol. 2002, 76, 432–435.
127. De Filette, M.; Ramne, A.; Birkett, A.; Lycke, N.; Lowenadler, B.; Min Jou, W.; Saelens, X.; Fiers, W. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006, 24, 544–551.
128. Guilliams, M.; Bruhns, P.; Saeys, Y.; Hammad, H.; Lambrecht, B.N. The function of Fcgamma receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 2014, 14, 94–108.
129. Purzel, J.; Schmitt, R.; Viertlboeck, B.C.; Gobel, T.W. Chicken IgY binds its receptor at the CH3/CH4 interface similarly as the human IgA: Fc alpha RI interaction. J. Immunol. 2009, 183, 4554–4559.
130. Viertlboeck, B.C.; Schweinsberg, S.; Hanczaruk, M.A.; Schmitt, R.; du Pasquier, L.; Herberg, F.W.; Gobel, T.W. The chicken leukocyte receptor complex encodes a primordial, activating, high-affinity IgY Fc receptor. Proc. Natl. Acad. Sci. USA 2007, 104, 11718–11723.
131. Magor, K.E.; Higgins, D.A.; Middleton, D.L.; Warr, G.W. One gene encodes the heavy chains for three different forms of IgY in the duck. J. Immunol. 1994, 153, 5549–5555.
132. Ramos, E.L.; Mitcham, J.L.; Koller, T.D.; Bonavia, A.; Usner, D.W.; Balaratnam, G.; Fredlund, P.; Swiderek, K.M. Efficacy and safety of treatment with an anti-M2e monoclonal antibody in experimental human influenza. J. Infect. Dis.2014, doi:10.1093/infdis/jiu539.
133. Song, A.; Myojo, K.; Laudenslager, J.; Harada, D.; Miura, T.; Suzuki, K.; Kuni-Kamochi, R.; Soloff, R.; Ohgami, K.; Kanda, Y. Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates. Antiviral Res. 2014, 111C, 60–68.
134. Schotsaert, M.; Ysenbaert, T.; Neyt, K.; Ibanez, L.I.; Bogaert, P.; Schepens, B.; Lambrecht, B.N.; Fiers, W.; Saelens, X. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal. Immunol. 2013, 6, 276–287.
135. Bodewes, R.; Kreijtz, J.H.; Rimmelzwaan, G.F. Yearly influenza vaccinations: A double-edged sword? Lancet Infect. Dis. 2009, 9, 784–788.
136. CDC. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices—United States, 2013–2014. MMWR Recomm. Rep. 2013, 62, 1–43.
137. Bodewes, R.; Kreijtz, J.H.; Baas, C.; Geelhoed-Mieras, M.M.; de Mutsert, G.; van Amerongen, G.; van den Brand, J.M.; Fouchier, R.A.; Osterhaus, A.D.; Rimmelzwaan, G.F. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLOS ONE 2009, 4, e5538.
138. Bodewes, R.; Kreijtz, J.H.; Geelhoed-Mieras, M.M.; van Amerongen, G.; Verburgh, R.J.; van Trierum, S.E.; Kuiken, T.; Fouchier, R.A.; Osterhaus, A.D.; Rimmelzwaan, G.F. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J. Virol. 2011, 85, 2695–2702.
139. Bodewes, R.; Kreijtz, J.H.; Hillaire, M.L.; Geelhoed-Mieras, M.M.; Fouchier, R.A.; Osterhaus, A.D.; Rimmelzwaan, G.F. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J. Gen. Virol.2010, 91, 1743–1753.
140. Bodewes, R.; Fraaij, P.L.; Geelhoed-Mieras, M.M.; van Baalen, C.A.; Tiddens, H.A.; van Rossum, A.M.; van der Klis, F.R.; Fouchier, R.A.; Osterhaus, A.D.; Rimmelzwaan, G.F. Annual vaccination against influenza virus hampers development of virus-specific CD8+ T cell immunity in children. J. Virol. 2011, 85, 11995–12000.
141. Liu, W.; Peng, Z.; Liu, Z.; Lu, Y.; Ding, J.; Chen, Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23, 366–371.
142. De Filette, M.; Fiers, W.; Martens, W.; Birkett, A.; Ramne, A.; Lowenadler, B.; Lycke, N.; Jou, W.M.; Saelens, X. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006, 24, 6597–6601.
143. Liu, W.; Chen, Y.H. High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: A novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur. J. Immunol.2005, 35, 505–514.
144. De Filette, M.; Min Jou, W.; Birkett, A.; Lyons, K.; Schultz, B.; Tonkyro, A.; Resch, S.; Fiers, W. Universal influenza A vaccine: Optimization of M2-based constructs. Virology 2005, 337, 149–161.
145. Sendi, P.; Locher, R.; Bucheli, B.; Battegay, M. Intranasal influenza vaccine in a working population. Clin. Infect. Dis. 2004, 38, 974–980.
146. Dynavax reports new phase 1a and phase 1b data for universal flu vaccine candidate. Available online: http://www.webcitation.org/query.php?url=http://investors.dynavax.com/releasedetail.cfm?ReleaseID=551606&refdoi=10.1186/1471–2458–13-s3-s14 (accessed on 22 February 2011).
147. Fiers, W.; de Filette, M.; el Bakkouri, K.; Schepens, B.; Roose, K.; Schotsaert, M.; Birkett, A.; Saelens, X. M2e-based universal influenza A vaccine. Vaccine 2009, 27, 6280–6283.
148. Safety study of recombinant M2e influenza-A vaccine in healthy adults (FLU-A). Available online: https://clinicaltrials.gov/ct2/show/NCT00819013?term=Acam-flu-A&rank=1 (accessed on 10 October 2008).
149. Smith, L.R.; Wloch, M.K.; Ye, M.; Reyes, L.R.; Boutsaboualoy, S.; Dunne, C.E.; Chaplin, J.A.; Rusalov, D.; Rolland, A.P.; Fisher, C.L; et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010, 28, 2565–2572.